Sichuan Hebang Biotechnology Co. Ltd. Class A

Sichuan Hebang Biotechnology Co. Ltd. Class A

SSSE:603077
1.98
CNY
+0.03
(+1.54%)
-0.04EPS
19.34BMarket Cap
Apr 27Next Earn

Total Valuation

CNY

As of September 30, 2026, Sichuan Hebang Biotechnology Co. Ltd. Class A carries a market capitalization of 19.34B, placing it among publicly traded companies globally. Its enterprise value stands at 21.15B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap19.34B
Enterprise Value21.15B

Important Dates

Sichuan Hebang Biotechnology Co. Ltd. Class A's next confirmed earnings release is scheduled for April 27, 2027.

Earnings Date4/27/2027

Share Statistics

As of September 30, 2026, Sichuan Hebang Biotechnology Co. Ltd. Class A has 8.83B shares outstanding.

Shares Outstanding8.83B

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 3.08, and the price-to-book ratio stands at 0.99.

PS Ratio3.08
PB Ratio0.99
P/TBV Ratio1.32

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 3.66 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 21.15B versus a market cap of 19.34B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.66

Financial Position

As of September 30, 2026, Sichuan Hebang Biotechnology Co. Ltd. Class A maintains a current ratio of 4.91, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 46.48, indicating elevated leverage, while an interest coverage ratio of -2.04 demonstrates limited ability to service its debt obligations.

Current Ratio4.91
Quick Ratio2.74
Debt / Equity46.48
Debt / EBITDA-36.99
Interest Coverage-2.04

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Sichuan Hebang Biotechnology Co. Ltd. Class A posted a negative return on equity (ROE) of -0.92, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.59, reflecting losses generated across the asset base. The company generates approximately 1.14M in revenue per employee across its workforce of 5,085.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.08 indicates how many times Sichuan Hebang Biotechnology Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-0.92
Return on Assets (ROA)-0.59
Revenue Per Employee1.14M
Employee Count5,085.00
Inventory Turnover1.08

Taxes

CNY

Over the twelve months ended September 30, 2026, Sichuan Hebang Biotechnology Co. Ltd. Class A recorded 76.18M in income tax expense. The company reported a pretax loss of -262.13M and -175.63M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax76.18M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Sichuan Hebang Biotechnology Co. Ltd. Class A's stock has declined approximately 18.85% over the past 52 weeks. The 50-day moving average sits at 2.17, while the 200-day moving average is 2.49.

52-Week Price Change-18.85%
50-Day Moving Average2.17
200-Day Moving Average2.49

Income Statement

CNY

Over the twelve months ended September 30, 2026, Sichuan Hebang Biotechnology Co. Ltd. Class A generated 5.78B in revenue and converted that into -175.63M in net income, yielding earnings per share of -0.04. EBITDA reached -247.50M, while operating income came in at 665.20M.

Revenue5.78B
Gross Profit1.26B
Operating Income665.20M
Pretax Income-262.13M
Net Income-175.63M
EBITDA-247.50M
EBIT-247.50M
Earnings Per Share (EPS)-0.04

Balance Sheet

CNY

As of September 30, 2026, Sichuan Hebang Biotechnology Co. Ltd. Class A holds 7.48B in cash and equivalents against 9.15B in total debt, resulting in a net debt position of 638.79M. Total book value stands at 19.57B, with working capital of 10.70B providing operational flexibility.

Cash & Cash Equivalents7.48B
Total Debt9.15B
Net Debt638.79M
Equity (Book Value)19.57B
Book Value Per Share2.22
Working Capital10.70B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-1.69B

Margins

Over the twelve months ended September 30, 2026, Sichuan Hebang Biotechnology Co. Ltd. Class A posted a gross margin of 21.84, reflecting its pricing power and cost economics. The operating margin of 11.50 and net profit margin of -3.04 provide insight into operational efficiency.

Gross Margin21.84
Operating Margin11.50
Pretax Margin-4.53
Profit Margin-3.04
EBITDA Margin-4.28

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Sichuan Hebang Biotechnology Co. Ltd. Class A paid dividends of 0.02 per share. The dividend payout ratio of -27.44 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -6.36, meaning Sichuan Hebang Biotechnology Co. Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.02
Payout Ratio-27.44
Shareholder Yield-6.36

Stock Splits

Sichuan Hebang Biotechnology Co. Ltd. Class A's most recent stock split took place on July 5, 2017 with a 25:66 split ratio.

Last Split Date7/5/2017
Split Ratio25:66

Scores

As of September 30, 2026, Sichuan Hebang Biotechnology Co. Ltd. Class A has an Altman Z-Score of 2.41, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.41